Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

AUTOR(ES)

Crusoe, Edvan De Queiroz; Higashi, Fabiana; Martinez, Gracia; Bittencourt, Rosane; Pinto Neto, Jorge Vaz; Sousa, Lais; Santucci, Rodrigo; Magalhães, Roberto José Pessoa; Colli, Gilberto; Nunes, Renata Ferreira Marques; Ribeiro, Glaciano; Nicacio, Jandir; Zanella, Karla Richter; Kutner, Jose Mauro; Magalhaes, Andre; Leao, Danielle; Hallack Neto, Abrahão Elias; Braga, Walter; Souza, Emanuella G; Guimaraes, Antonio Julio A.M.; Durigon, Giovanna Steffenello; Laks, Dani; Maiolino, Angelo; Hungria, Vania Tietsche de Moraes

FONTE

Hematol., Transfus. Cell Ther.

DATA DE PUBLICAÇÃO

2020-06

RESUMO

ABSTRACT Background: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than double combinations. However, comparisons among different triple combinations are rare in the literature. Methods: We retrospectively compared two triple combinations comprising bortezomib, cyclophosphamide and dexamethasone (VCD) versus thalidomide, cyclophosphamide and dexamethasone (CTD), and aimed at identifying which of the two combinations would yield better response rates following four induction cycles prior to hematopoietic cell transplantation in patients with untreated multiple myeloma. Results: We retrospectively reviewed the medical records of 311 patients from 24 different centers.The VCD regimen was used as induction therapy by 117 (37.6%) patients, whereas 194 (62.4%) patients received the CTD regimen. After four cycles of induction on an intention-to-treat basis, 54% of the patients in the VCD group achieved at least very good partial response versus 42.8% in the CTD group (p = 0.05). We observed no difference in neuropathy or thrombotic events rates among the two regimens. Conclusion: Our results corroborate the superiority of the triple combination regimes containing bortezomib over the triple combination with thalidomide as pre ASCT induction therapy in MM.

Documentos Relacionados

• Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
• Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
• Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
• Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
• Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone